Cytotoxicity of alkaloids isolated from Peganum harmala seeds

Pakistan Journal of Pharmaceutical Sciences

Volumn 26, Issue 4, 2013, Pages 699-706

  Lamchouri, Fatima ^a   Zemzami, Mustapha ^b   Jossang, Akino ^c   Settaf, Abdellatif ^d   Israili, Zafar H ^e   Lyoussi, Badiaa ^f  

^a Faculté Polydisciplinaire de Taza   (Morocco)

^b U de Controle des Plants   (Morocco)

^c UNIVERSITÉ DE LIMOGES   (France)

^d MOHAMMED V UNIVERSITY   (Morocco)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f SIDI MOHAMED BEN ABDELLAH UNIVERSITY   (Morocco)

Author keywords

Alkaloids; Anticancer activity; Antiproliferating activity; Cytotoxicity; Harmalacidine; Harmine; Murine tumor cells; Peganine (vasicine); Peganum harmala; Phytotherapy; Vasicinone

Indexed keywords

ALKALOID; CELL DNA; HARMALICIDINE; HARMINE; THYMIDINE DERIVATIVE; TOTAL ALKALOIDAL FRACTION; UNCLASSIFIED DRUG; VASICINE; VASICINONE;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CARCINOMA; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CYTOTOXICITY; GROWTH INHIBITION; IC 50; IN VITRO STUDY; LEUKEMIA CELL LINE; NONHUMAN; PEGANUM HARMALA; PLANT SEED; RAT; SARCOMA; TUMOR CELL LINE; WISTAR RAT;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL PROLIFERATION; HARMINE; HUMANS; PEGANUM; QUINAZOLINES; RATS; RATS, WISTAR; SEEDS;

EID: 84880304836     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Astulla A, Zaima K, Matsuno Y, Hirasawa Y, Ekasari W, Widyawaruyanti A, Cholies Zaini N and Morita H (2008). Alkaloids from the seeds of Peganum harmala showing antiplasmodial and vasorelaxant activities. J. Nat. Med., 62: 470-472.
2. Ayoub MT, Al-Allaf TAK and Rashan LJ (1994). Antiproliferative activity of harmalol. Fitoterapia, 65: 14-18.
3. Berrougui H, López-Lázaro M, Martin-Cordero C, Mamouchi M, Ettaib A and Herrera MD (2005). Cytotoxic activity of methanolic extract and two alkaloids extracted from seeds of Peganum harmala L. J. Nat. Remedies, 5: 41-45.
4. Berrougui H, Isabelle M, Cloutier M, Hmamouchi M and Khalil A (2006a). Protective effects of Peganum harmala L. extract, harmine and harmaline against human low-density lipoprotein oxidation. J. Pharm. Pharmacol., 58: 967-974.
5. Berrougui H, Martin-Cordero C, Khalil A, Hmamouchi M, Ettaib A, Marhuenda E and Herrera MD (2006b). Vasorelaxant effects of harmine and harmaline extracted from Peganum harmala L. seeds in isolated rat aorta. Pharmacol. Res., 54: 150-157.
6. Bremner P, Rivera D, Calzado MA, Obon C, Inocencio C, Beckwith C, Fiebich BL, Muñoz F and Heinrich M (2009). Assessing medicinal plants from South-Eastern Spain for potential anti-inflammatory effects targeting nuclear factor-Kappa B and other pro-inflammatory mediators. J. Ethnopharmacol., 124: 295-305.
7. Cao M-R., Li Q, Liu Z-L, Liu H-H, Wang W, Liao X.-L., Pan YL and Jiang JW (2011). Harmine induces apoptosis in HepG2 cells via mitochondrial signaling pathway. Hepatobiliary Pancr. Dis. Int., 10: 599-604.
8. Cao R, Peng W, Chen H, Ma Y, Liu X, Hou X, Guan H and Xu A (2005b). DNA binding properties of 9-substituted harmine derivatives. Biochem. Biophys. Res. Commun., 338: 1557-1563.
9. Cassileth BR and Deng G (2004). Complementary and alternative therapies for cancer. Oncologist, 9: 80-89.
10. Chen Q, Chao R, Chen H, Hou X, Yan H, Zhou S, Peng W and Xu A (2004). Antitumor and neurotoxic effects of novel harmine derivatives and structure-activity relationship analysis. Int. J. Cancer, 114: 675-682.
11. Dennis T, Fanous M and Mousa S. (2009). Natural products for chemopreventive and adjunctive therapy in oncologic disease. [Review] [66 refs] Nutr. Cancer, 61: 587-597.
12. Derakhshanfar A, Oloumi MM and Mirzaie M (2010). Study on the effect of Peganum harmala extract on experimental skin wound healing in rat: Pathological and biomechanical findings. Comparat. Clin. Pathol., 19: 169-172.
13. Dewick PM (2009). Medicinal Natural Products: A Biosynthetic Approach, 3rd ed. Chichester, UK, Wiley, p.539.
14. El-Saad El-Rifaie M (1980). Peganum harmala: its used in certain dermatoses. Int. J. Dermatol., 19: 221-222.
15. Farouk L, Laroubi A, Aboufatima R, Benharref A and Chait A (2008). Evaluation of the analgesic effect of alkaloid extract of Peganum harmala L.: Possible mechanisms involved. J. Ethnopharmacol., 115: 449-454.
16. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer, 127: 2893-2917.
17. Gu B, Wu D, Li M and Lu H (2000). Potentiation of docetaxel antitumor activity by batimastat against mouse forestomach carcinoma. J. Environm. Pathol. Toxicol. Oncol., 19: 375-382.
18. Hernlund E, Ihrlund LS, Khan O, Ates YO, Linder S, Panaretakis T and Shoshan MC (2008). Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Int. J. Cancer, 123: 476-483.
19. Herraiz T, González D, Ancín-Azpilicueta C, Arán VJ and Guillén H (2010). ß-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem. Toxicol., 48: 839-845.
20. Hudson JB, Graham EA, Fong R, Hudson LL and Towers GH (1986). Further studies on the antiviral activity of harmine, a photoactive beta-carboline alkaloid. Photochem. Photobiol., 44: 483-487.
21. Im J-H, Jin Y-R, Lee J-J, Yu J-Y, Han X-H, Im S-H, Hong J-T, Yoo H-S, Pyo M-Y and Yun Y-P (2009). Antiplatelet activity of ß-carboline alkaloids from Perganum harmala: A possible mechanism through inhibiting PLC?2 phosphorylation. Vasc. Pharmacol., 50: 147-152.
22. Ishida J, Wang HK, Bastow KF, Chang QH and Lee KH (1999). Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs. Bioorg. Med. Chem. Lett., 9: 3319-3324.
23. Ishida J, Wang H-K, OyamaM, Cosentino ML, Hu C-Q and Lee K-H (2001). Anti-AIDS Agents. 46. Anti-HIV activity of harman, an anti-HIV principle from Symplocos setchuensis, and its derivatives. J. Nat. Prod., 64: 958-960.
24. Jahaniani F, Ebrahimi SA, Rahbar-Roshandel N and Mahmoudian M (2005). Xanthomicrol is the main cytotoxic component of Dracocephalum kotschyii and a potential anti-cancer agent. Phytochemistry, 66: 1581-1592.
25. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D (2011). Global cancer statistics. CA: Cancer J. Clin. 61: 69-90.
26. Erratu: CA Cancer J Clin. 2011; 61:134
27. Lamchouri F, Jossang A, Bodo B, Cherrah Y and Settaf A (2008). Vasicinone, harmine, peganine et harmalacidine, quatre alcaloïdes bioactifs isolés des graines de Peganum harmala. Biolog Santé, 1: 105-117.
28. Lamchouri F, Settaf A, Cherrah Y, Hassar M, Zemzami M, Atif N, Nadori EB, Zaid A and Lyoussi B (2000). In vitro cell-toxicity of Peganum harmala alkaloids on cancerous cell-lines. Fitoterapia, 71: 50-54.
29. Lamchouri F, Settaf A, Cherrah Y, Zemzami M, Lyoussi B, Zaid A, Atif N and Hassar M (1999). Antitumour principles from Peganum harmala seeds. Thérapie, 54: 753-758.
30. Ma Y and Wink M (2010). The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother. Res., 24: 146-149.
31. Mahmoudian M, Jalilpour H and Salehian P (2002). Toxicity of Peganum harmala: Review and a case report. Iranian J. Pharmacol. Therap., 1: 1-4.
32. Mansouri N and Farzin D (2009). Antidepressant-like effect of harmane and other ß-carbolines in a mouse forced-swim test. Eur. J. Neurol., 16(Suppl. 3): 451.
33. Miller S, Stagl J, Wallerstedt DB, Ryan M and Mansky PJ (2008). Botanicals used in complementary and alternative medicine treatment of cancer: clinical science and future perspectives. [Review]. Exp. Opin. Investig. Drugs, 17: 1353-1364.
34. Mirzaei M (2007). Treatment of natural tropical theileriosis with the extract of the plant Peganum harmala. Korean J. Parasitol., 45: 267-271.
35. Nafisi S, Bonsaii M, Maali P, Khalilzadeh MA and Manouchehri F (2010a). ß-Carboline alkaloids bind DNA. J. Photochem. Photobiol. B: Biology, 100: 84-91.
36. Nafisi S, Malekabady ZM and Khalilzadeh MA (2010b). Interaction of ß-carboline alkaloids with RNA. DNA Cell Biol., 29: 753-761.
37. Papadopoulou MV, Ji M and Bloomer WD (2003). Synergistic interaction between cyclophosphamide or paclitaxel and the bioreductive compound NLCPQ-1, in vivo. Oncol. Res., 13: 561-566.
38. Phillips HJ (1973) Dye exclusion tests for cell viability. In: Tissue Culture: Methods and Applications. Kruse Jr PF, Patterson Jr MK (eds) Academic Press, New York, pp. 406-408.
39. Pitre S and Srivastava SK (1987). Two new anthraquinones from the seeds of Peganum harmala. Planta Med., 53: 106-107.
40. Pulpati H, Biradar YS and Rajani M (2008). Highperformance thin-layer chromatography densitometric method for the quantification of harmine, harmaline, vasicine, and vasicinone in Peganum harmala. J. AOAC Int., 91: 1179-1185.
41. Rashan LJ, Adaay MH and Al-Khazraji AL (1989). In vitro antiviral activity of the aqueous extract from the seeds of Peganum harmala. Fitoterapia, 60: 365-367.
42. Schulman M, Wilde CD and Kohler G (1978). A better cell line for making hybridomas secreting specific antibodies. Nature, 276: 269-270.
43. Shahverdi AR, Ostad SN, Khodaee S, Bitarafan L, Monsef-Esfahani HR, Jamalifar H, Nikavar B and Mohseni M (2008). Antimicrobial and cytotoxicity potential of Peganum harmala smoke. Pharmacog. Magaz., 4: 236-240.
44. Shu L, Cheung KL, Khor TO, Chen C and Kong AN (2010). Phytochemicals: Cancer chemoprevention and suppression of tumor onset and metastasis. [Review]. Cancer Metastasis Rev., 29: 483-502.
45. Singh AB, Chaturvedi JP, Narender T and Srivastava AK (2008). Preliminary studies on the hypoglycemic effect of Peganum harmala L. seeds ethanol extract on normal and streptozotocin induced diabetic rats. Indian J. Clin. Biochem., 23: 391-393.
46. Sharaf M, el-Ansari MA, Matlin SA and Saleh NA (1997). Four flavonoid glycosides from Peganum harmala. Phytochemistry, 44: 533-536.
47. Smithson J, Britten N, Paterson C, Lewith G and Evans M (2012). The experience of using complementary therapies after a diagnosis of cancer: A qualitative synthesis. [Review]. Health (London), 16: 19-39.
48. Sobhani AM, Ebrahimi SA and Mahmoudian M (2002). An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seeds extract and its beta-carboline alkaloids. J. Pharm. Pharmaceut. Sci., 5: 19-23.
49. Song Y, Kesuma D, Wang J, Deng Y, Duan J, Wang JH and Qi RZ (2004). Specific inhibition of cyclindependent kinases and cell proliferation by harmine. Biochem. Biophys. Res. Commun., 317: 128-132.
50. Song ZY, Liu JR, Lu XL and Wang LJ (2006). Harmine induces apoptosis in human SGC-7901 cells. Zhong yao cai = Zhongyaocai = J. Chinese Med. Materials, 29: 571-573.
51. Urien S (1995). Micropharm -K, a microcomputer interactive program for the analysis and simulation of pharmacokinetic processes. Pharmaceut. Res., 12: 1225-1230.
52. Wang S, Wang Q, Wang Y, Liu L, Weng X, Li G, Zhang X, Zhou X (2008). Novel anthraquinone derivatives: Synthesis via click chemistry approach and their induction of apoptosis in BGC gastric cancer cells via reactive oxygen species (ROS)-dependent mitochondrial pathway. Bioorg. Med. Chem. Lett., 18: 6505-6508.
53. Zheng X-Y, Zhang Z-J, Chou G-X, Wu T, Cheng X-M, Wang C-H and Wang Z-T (2009). Acetylcholinesterase inhibitive activity-guided isolation of two new alkaloids from seeds of Peganum nigellastrum Bunge by an in vitro TLC-bioautographic assay. Arch. Pharmacal. Res., 32: 1245-1251.
54. Zaker F, Oody A and Arjmand A (2007). A study on the antitumoral and differentiation effects of Peganum harmala derivatives incombination with ATRA on leukaemic cells. Arch. Pharmacal. Res., 30: 844-849.